• Compass Pathways welcomed White House executive order aimed at accelerating research and access for psychedelic treatments for serious mental illness.
• CEO Kabir Nath framed order as supporting faster access while maintaining scientific rigor.
• Compass highlighted two positive phase 3 trials of COMP360 synthetic psilocybin in treatment-resistant depression, citing effects within one day with durability lasting at least 6 months for responders.
• Company said it is working with FDA on rolling submission and review for COMP360 in treatment-resistant depression.
• Compass cited potential for accelerated regulatory and rescheduling processes under order, positioning company to move quickly if COMP360 is cleared.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260418890886) on April 18, 2026, and is solely responsible for the information contained therein.